Oncologia Medica 1, Istituto Oncologico Veneto-IRCCS, Padova, Italy.
Urol Oncol. 2012 May-Jun;30(3):240-6. doi: 10.1016/j.urolonc.2009.12.018. Epub 2010 Apr 24.
An improved understanding of the biological pathways deregulated in renal cell carcinoma has led to the development of various targeted agents, changing dramatically the therapeutic options for this disease. However, despite numerous opinions and guidelines, the optimal treatment still remains uncertain. In this review, we analyze the most recent published reports regarding the agents sunitinib, bevacizumab, sorafenib, temsirolimus, and everolimus. Moreover, we assess the novel targeted drugs pazopanib and axitinib. In addition, given the likely lack of cross-resistance between these targeting agents, we discuss sequential and combination targeted therapy in metastatic renal cell carcinoma, analyzing the most recent data.
对肾细胞癌中失调的生物学途径的认识的提高，导致了各种靶向药物的发展，这极大地改变了该疾病的治疗选择。然而，尽管有许多意见和指南，最佳治疗方法仍然不确定。在这篇综述中，我们分析了关于舒尼替尼、贝伐珠单抗、索拉非尼、替西罗莫司和依维莫司的最新发表的报告。此外，我们评估了新型靶向药物帕唑帕尼和阿昔替尼。此外，鉴于这些靶向药物之间可能缺乏交叉耐药性，我们讨论了转移性肾细胞癌中的序贯和联合靶向治疗，分析了最新的数据。
